AAMDSIF to make news at ASH Conference | Aplastic Anemia & MDS International Foundation

AAMDSIF to make news at ASH Conference

Original Publication Date: 
Thursday, December 1, 2016
Article Source: 

November 30, 2016
Contact: Barbara Holzer, holzer@aamds.org, (301) 279-7202, x106
Alice Houk, houk@aamds.org, 301-279-7202 x101

Pharma, Docs Can Now Put Their Mouth Where Their Money Is; Patient Advocacy Group to Hold Swabbing Event at ASH

AAMDSIF to Include Be-The-Match Drive at its ASH Exhibit Booth

BETHESDA, MARYLAND – On Dec. 3 when the doors open at the 58th Annual Meeting of the American Society of Hematology (ASH) in San Diego, the world’s largest professional association of clinicians and scientists working on blood diseases will provide its huge crowd of attendees with a beehive of activity. Yet among the scores of exhibitors who will be there, only one will actually get in the faces of conference-goers.

The Aplastic Anemia and MDS International Foundation (AAMDSIF) will be offering a DNA swabbing event, to be held in conjunction with Be The Match, operated by the National Marrow Donor Program. For 25 years, this organization has matched the DNA of healthy donors with patients in need of a transplant due to life-threatening blood diseases like MDS (myelodysplastic syndromes), aplastic anemia and leukemia. While bone marrow drives are relatively common at sporting events, schools and churches, this one will reach a large portion of the population most dedicated to treating blood cancer patients, conducting research and looking for the all-important cures.   

Another unusual offering from AAMDSIF will come in the form of a success story. In addition to patient education and support services, the Foundation provides research grants to further the study of bone marrow failure diseases like MDS. One such grant to study PNH (paroxysmal nocturnal hemoglobinuria) went to Dr. David Araten, assistant professor in the Division of Hematology at the NYU School of Medicine in New York City. His work, “Analysis of platelets by flow cytometry in patients with PNH”, which will be presented as a poster on Dec. 3, helps to explain why patients with PNH develop blood clots and may help predict which patients are more likely to develop this complication. PNH is a condition that occurs in patients with aplastic anemia, and Dr. Araten’s previous work, also supported by AAMDSIF, dealt with the relationship between these two diseases.

For more information and to schedule an interview with AAMDSIF CEO Kathleen Weis and/or Dr. David Araten, please contact one of the parties listed above.

The Aplastic Anemia and MDS International Foundation (AAMDSIF) has been arming patients and families with the information they need to fight bone marrow failure disease since 1983. The organization sponsors innovative and collaborative research through the MDS Clinical Research Consortium and with its own research grant program. Based in Bethesda, MD, the Foundation has received Charity Navigator’s coveted 4-star rating for 11 consecutive years.